The sixth Clinical & Pharmaceutical Solutions through Analysis (CPSA) was successfully held in Renaissance Shanghai Pudong Hotel on April 20th- 22th, 2016. More than 200 people were attracted, who are from multinational pharmaceutical companies, domestic CRO, biomedical research institutes and executives, experts and scholars from universities. The theme of this conference is “Innovative approaches to reduce attrition and predict clinical outcomes.” CPSA is an international conference in the field of chemical and pharmaceutical structural analysis, which has been held in the United States for seventeen years by 2015. CPSA Shanghai is mainly geared towards professionals who are interested in the development trend of emerging market.
In terms of thematic and roundtable discussions, scientists shared ideas about new technologies and applications regarding current biochemical assays, such as the progress of metabolomics platform, assay for the detection of small molecule and mass spectrometry analysis on tumor diagnosis related issues. In order to repay sponsor, the conference organizers set up a beautiful poster wall, not only to display the scientific research achievements, but also to give a pleasant cruise to participants.
ChemPartner is famous for drug screening in the early phases of drug discovery and developed nearly 100 in vivo techniques in broad animal species for many clients to understand PK/PD correlation. For this time, DMPK team introduced in vivo toxicokinetic study in SD rats and in vitro metabolic stability study in liver microsomes, which revealed the inherent advantages and comprehensive strength on biological analysis (GLP and Non-GLP), in vitro ADME, in vivo DMPK and Toxicology research.
